Targeted inhibition of sp1-mediated transcription for antiangiogenic therapy of metastatic human gastric cancer in orthotopic nude mouse models

International Journal of Oncology

Volumn 33, Issue 1, 2008, Pages 161-167

  Wang, Liwei ^a,b,c   Guan, XiaoHong ^a   Zhang, Jun ^b,c   Jia, Zhiliang ^c   Wei, Daoyan ^c   Li, Qiang ^c   Yao, James ^c   Xie, Keping ^c  

^a NANJING MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Angiogenesis; Metastasis; Mitharamycin A; Sp1; VEGF

Indexed keywords

BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; MITHRAMYCIN; MITHRAMYCIN A; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; DRUG DERIVATIVE; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; LOW DRUG DOSE; METASTASIS INHIBITION; MONOTHERAPY; MOUSE; NONHUMAN; NUDE MOUSE; POSITIVE FEEDBACK; PRIORITY JOURNAL; STOMACH CANCER; SURVIVAL RATE; UPREGULATION; ANIMAL; DISEASE MODEL; DRUG ANTAGONISM; GENETIC TRANSCRIPTION; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY; STOMACH TUMOR; TUMOR CELL LINE; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; FEMALE; HUMANS; MICE; MICE, NUDE; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PLICAMYCIN; SP1 TRANSCRIPTION FACTOR; STOMACH NEOPLASMS; TRANSCRIPTION, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 51049111879     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.33.1.161     Document Type: Article

References (47)

1. Parkin DM, Bray F, Ferlay J, et al: Global cancer statistics. CA Cancer J Clin 55: 74-108, 2005.
2. Parkin DM, Pisani P and Ferlay J: Estimates of the worldwide incidence of 25 major cancers. Int J Cancer 80: 827-841, 1999.
3. Zheng L, Wang L, Ajani J, et al: Molecular basis of gastric cancer development and progression. Gastric Cancer 7: 61-77, 2004.
4. Chan AO, Luk JM and Hui WM: Molecular biology of gastric carcinoma: from laboratory to bedside. J Gastroenterol Hepatol 14: 1150-1160, 1999.
5. Xie K, Wei D and Huang S: Transcriptional anti-angiogenesis therapy of human pancreatic cancer. Cytokine Growth Factor Rev 17: 147-156, 2006.
6. Siewert JR, Bottcher K, Stein HJ, et al: Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg 228: 449-461, 1998.
7. Xie K: Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev 12: 375-391, 2001.
8. Xie K, Wei D, Shi Q, et al: Constitutive and inducible expression and regulation of vascular endothelial growth factor. Cytokine Growth Factor Rev 15: 297-324, 2004.
9. Guo YS, Beauchamp, RD, Jin GF, et al: Insulinlike growth factor-binding protein modulates the growth response to insulinlike growth factor 1 by human gastric cancer cells. Gastroenterology 104: 1595-1604, 1993.
10. Yoshikawa T, Tsuburaya A, Kobayashi O, et al: Plasma concentrations of VEGF and bFGF in patients with gastric carcinoma. Cancer Lett 153: 7-12, 2000.
11. Sier CF, Kubben FJ, Ganesh S, et al: Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer 74: 413-417, 1996.
12. Lu M, Jiang Y and Wang R: The relationship of vascular endothelial growth factor and angiogenesis to the progression of gastric carcinoma. Zhonghua Bing Li Xue Za Zhi 27: 278-281, 1998.
13. Giatromanolaki A, Koukourakis MI, Stathopoulos GP, et al: Angiogenic interactions of vascular endothelial growth factor, of thymidine phosphorylase, and of p53 protein expression in locally advanced gastric cancer. Oncol Res 12: 33-41, 2000.
14. Takahashi R, Tanaka S, Kitadai Y, et al: Expression of vascular endothelial growth factor and angiogenesis in gastrointestinal stromal tumor of the stomach. Oncology 64: 266-274, 2003.
15. Du JR, Jiang Y, Zhang YM, et al: Vascular endothelial growth factor and microvascular density in esophageal and gastric carcinomas. World J Gastroenterol 9: 1604-1606, 2003.
16. La Rosa S, Uccella S, Finzi G, et al: Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: correlation with microvessel density and clinicopathologic features. Hum Pathol 34: 18-27, 2003.
17. Kaneko T, Konno H, Baba M, et al: Urokinase-type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer. Cancer Sci 94: 43-49, 2003.
18. Sanz-Ortega J, Steinberg SM, Moro E, et al: Comparative study of tumor angiogenesis and immunohistochemistry for p53, c-ErbB2, c-myc and EGFr as prognostic factors in gastric cancer. Histol Histopathol 15: 455-462, 2000.
19. Tenderenda M, Rutkowski P, Jesionek-Kupnicka D, et al: Expression of CD34 in gastric cancer and its correlation with histology, stage, proliferation activity, p53 expression and apoptotic index. Pathol Oncol Res 7: 129-134, 2001.
20. Chen CN, Cheng YM, Lin MT, et al: Association of color Doppler vascularity index and microvessel density with survival in patients with gastric cancer. Ann Surg 235: 512-518, 2002.
21. Hironaka S, Hasebe T, Kamijo T, et al: Biopsy specimen microvessel density is a useful prognostic marker in patients with T(2-4)M(0) esophageal cancer treated with chemoradiotherapy. Clin Cancer Res 8: 124-130, 2002.
22. Kim HS, Kang HS, Messam CA, et al: Comparative evaluation of angiogenesis in gastric adenocarcinoma by nestin and CD34. Appl Immunohistochem Mol Morphol 10: 121-127, 2002.
23. Shi Q, Le X, Peng Z, et al: Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res 61: 4143-4154, 2001.
24. Wang L, Wei D, Le X, et al: Transcription factor Sp1 expression is a significant predictor of survival in human gastric cancer. Clin Cancer Res 9: 6371-6380, 2003.
25. Black AR, Black JD and Azizkhan-Clifford J: Sp1 and kruppel-like factor family of transcription factors in cell growth regulation and cancer. J Cell Physiol 188: 143-160, 2001.
26. Li L, He S, Sun JM, et al: Gene regulation by Sp1 and Sp3. Biochem Cell Biol 82: 460-471, 2004.
27. Mukhopadhyay D and Datta K: Multiple regulatory pathways of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in tumors. Semin Cancer Biol 14: 123-130, 2004.
28. Abdelrahim. M, Smith R III, Burghardt R and Safe S: Role of Sp proteins in regulation of vascular endothelial growth factor expression and proliferation of pancreatic cancer cells. Cancer Res 64: 6740-6749, 2004.
29. Safe S and Abdelrahim M: Sp transcription factor family and its role in cancer. Eur J Cancer 41: 2438-2448, 2005.
30. Wohlert SE, Kunzel E, Machinek R, et al: The structure of mithramycin reinvestigated. J Nat Prod 62: 119-121, 1999.
31. Prado L, Lornbo F, Brana AF, et al: Analysis of two chromosomal regions adjacent to genes for a type II polyketide synthase involved in the biosynthesis of the antitumor polyketide mithramycin in Streptomyces argillaceus. Mol Gen Genet 261: 216-225, 1999.
32. Hall TJ, Schaeublin M and Chambers TJ: The majority of osteoclasts require mRNA and protein synthesis for bone resorption in vitro. Biochem Biophys Res Commun 195: 1245-1253, 1993.
33. Remsing LL, Bahadori HR, Carbone GM, et al: Inhibition of c-src transcription by mithramycin: structure-activity relationships of biosynthetically produced mithramycin analogues using the c-src promoter as target. Biochemistry 42: 8313-8324, 2003.
34. Chatterjee S, Zaman K, Ryu H, et al: Sequence-selective DNA binding drugs mithramycin A and chromomycin A3 are potent inhibitors of neuronal apoptosis induced by oxidative stress and DNA damage in cortical neurons. Ann Neurol 49: 345-354, 2001.
35. Blume SW, Snyder RC, Ray R, et al: Mithramycin inhibits SP1 binding and selectively inhibits transcriptional activity of the dihydrofolate reductase gene in vitro and in vivo. J Clin Invest 88: 1613-1621, 1991.
36. Tagashira M, Kitagawa T, Isonishi S, et al: Mithramycin represses MDR1 gene expression in vitro, modulating multidrug resistance. Biol Pharm Bull 23: 926-929, 2000.
37. Duverger V, Murphy AM, Sheehan D, et al: The anticancer drug mithramycin A sensitises tumour cells to apoptosis induced by tumour necrosis factor (TNF). Br J Cancer 90: 2025-2031, 2004.
38. Koutsodontis G and Kardassis D: Inhibition of p53-mediated transcriptional responses by mithramycin A. Oncogene 23: 9190-9200, 2004.
39. Weidner N, Semple JP, Welch WR, et al: Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324: 1-8, 1991.
40. Kanai M, Wei D, Li Q, et al: Kruppel-like factor 4 represses Sp1 expression and contributes to its tumor suppressor activity in human pancreatic and gastric cancer. Clin Cancer Res 12: 6395-6402, 2006.
41. Morabito A, De Maio E, Di Maio M, et al: Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist 11: 753-764, 2006.
42. Yazici YD, Kim S, Jasser SA, et al: Antivascular therapy of oral tongue squamous cell carcinoma with PTK787. Laryngoscope 115: 2249-2255, 2005.
43. Prox D, Becker C, Pirie-Shepherd SR, et al: Treatment of human pancreatic cancer in mice with angiogenic inhibitors. World J Surg 27: 405-411, 2003.
44. Wiedmann MW and Caca K: Molecularly targeted therapy for gastrointestinal cancer. Curr Cancer Drug Targets 5: 171-193, 2005.
45. Jain RK: Tumor angiogenesis and accessibility: rate of vascular endothelial growth factor. Semin Oncol 29: 3-9, 2002.
46. Blagosklonny MV: How Avastin potentiates chemotherapeutic drugs: action and reaction in antiangiogenic therapy. Cancer Biol Ther 4: 1307-1310, 2005.
47. Kowanetz M and Ferrara N: Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res 12: 5018-5022, 2006.